Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Eisai
< Previous
1
2
Next >
Lecanemab Receives Priority Review Status in Japan
January 29, 2023
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
January 09, 2023
From
Eisai
Via
JCN Newswire
Tickers
ESALY
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
January 09, 2023
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
December 22, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
December 19, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases
December 14, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
December 01, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
November 29, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
November 23, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
April 01, 2022
From
Eisai
Via
ACN Newswire
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 29, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
November 22, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
March 28, 2022
From
Eisai
Via
ACN Newswire
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
March 22, 2022
From
Eisai
Via
ACN Newswire
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
March 15, 2022
From
Eisai
Via
ACN Newswire
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
March 15, 2022
From
Eisai
Via
ACN Newswire
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
February 25, 2022
From
Eisai
Via
ACN Newswire
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
February 01, 2022
From
Eisai
Via
ACN Newswire
Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
January 31, 2022
From
Eisai
Via
ACN Newswire
Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases
January 28, 2022
From
Eisai
Via
ACN Newswire
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
January 28, 2022
From
Eisai
Via
ACN Newswire
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
January 20, 2022
From
Eisai
Via
ACN Newswire
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
January 19, 2022
From
Eisai
Via
ACN Newswire
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
January 19, 2022
From
Eisai
Via
ACN Newswire
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
January 17, 2022
From
Eisai
Via
ACN Newswire
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)
January 13, 2022
From
Eisai
Via
ACN Newswire
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
January 06, 2022
From
Eisai
Via
ACN Newswire
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation
December 24, 2021
From
Eisai
Via
ACN Newswire
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States
December 21, 2021
From
Eisai
Via
ACN Newswire
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia
December 20, 2021
From
Eisai
Via
ACN Newswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
